SLATTERY JOSEPH P sold $113K of REPL

SLATTERY JOSEPH P sold 5,200 shares of Replimune Group, Inc. (REPL) at $21.80 ($0.11M total) on 2026-11-09.

Original reporting
SEC EDGAR · SLATTERY JOSEPH P
Published Nov 10, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 9:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$REPL
Bearish
medium confidence
Mentioned
$REPL
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$REPLBearishLow
01

Why it matters

A director's sale of $113K is modest but may attract short‑term attention.

02

Market read

The filing provides a fresh, primary‑source data point but its small scale limits trading relevance.

03

What to watch

The director may be diversifying holdings; no change in company fundamentals.

Relevance 4/10Novelty 3/10Timing: after‑hours filing

Background

SEC Form 4 filing discloses insider transactions; investors monitor these for signals.

Company-level read

Ticker impact

$REPLBearishMedium confidence
Context

Director Joseph Slattery sold 5,200 shares for $113,360, reducing his stake to 1,467 shares.

Expected impact

likely slight pressure as the market prices in the director's sell.

Evidence & confidence

A director's open‑market sale, though modest in size, can be interpreted as a lack of confidence and may prompt short‑term selling.

Market effects

Minimal impact on the biotech sector; the sale is company‑specific.

None

None

Counterpoint

The sale could be routine portfolio rebalancing rather than a negative signal.

Key entities

  • Replimune Group, Inc.

    Biotech firm listed on NASDAQ under ticker REPL.

  • Joseph Slattery

    Director of Replimune Group, Inc.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$REPLHigh

Replimune Soars 17% as TUDRIQEV Melanoma Launch Draws “Enthusiastic” Response From Physicians

Replimune (REPL) shares rose 17% after reporting strong initial uptake of TUDRIQEV, its melanoma treatment, with over 15 institutions prescribing it in three weeks. The company has $307.8 million in cash. TUDRIQEV is used with Bristol Myers Squibb's (BMY) Opdivo and targets tumors not treated by Amgen's (AMGN) Imlygic. Analysts expect revenue growth, but no sales figures are available yet.

$REPLMed

Replimune (REPL) Q2 2027 Earnings Call Transcript

Replimune (REPL) reported Q2 2027 earnings, highlighting the commercial launch of TUDRIQEV. The company noted strong physician interest and rapid adoption, with over 15 institutions prescribing the drug in less than 20 business days. Replimune reported a net loss of $57.1 million for the quarter, with $307.8 million in cash reserves. The company expects to report first product revenue in Q3 2027.

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$REPLMed

Replimune Reports Fiscal Q2 2027 Results, $57.1 Million Net Loss

Replimune reported a net loss of $57.1M for Q2 2027, down from $83.1M a year earlier. Cash reserves were $307.8M. R&D and operating expenses decreased. TUDRIQEV, for advanced melanoma, launched commercially in the U.S. in October, with over 15 institutions prescribing it. The company is engaging with priority accounts and advancing clinical trials.